(1S,2R) Bortezomib
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
(1S,2R) Bortezomib Product Information
(1S,2R) Bortezomib is listed under Chiral and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Bortezomib. The product is supplied by Clearsynth under CAT No. CS-O-20087.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
(1S,2R) Bortezomib
CAS No.
1132709-16-0
CAT No.
CS-O-20087
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C19H25BN4O4
Molecular Weight
384.2
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
(1S,2R) Bortezomib is supplied with detailed characterization data compliant with regulatory guideline. (1S,2R) Bortezomib can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Bortezomib.
Overview
"(1S,3R)-Bortezomib is an diastereomer of Bortezomib , the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus"
Synonyms
(1S,2R) Bortezomib
Application Notes
"(1S,3R)-Bortezomib is an diastereomer of Bortezomib , the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus"
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.